 Calcineurin inhibitors do remain the corner stone of immunosuppression at the present time, and even more so in the context of steroid minimization. It would thus be very important to determine if one of the two calcineurin inhibitors available on the market has a more favourable metabolic profile specifically for patients with pre-existing diabetes. Direct comparison between Neoral micro-emulsion formulation of CSA and Prograf has never been made in context of short steroid taper and specifically for non-insulin dependent diabetic patients. 